Last update 01 Nov 2024

Cabiralizumab

Overview

Basic Info

Drug Type
Monoclonal antibody
Synonyms
Target
Mechanism
CSF-1R antagonists(Colony stimulating factor 1 receptor antagonists)
Originator Organization
Inactive Organization-
Drug Highest PhasePhase 2
First Approval Date-
RegulationOrphan Drug (US)
Login to view timeline

External Link

KEGGWikiATCDrug Bank
---

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Pancreatic AdenocarcinomaPhase 2
TW
18 Dec 2017
Advanced Pancreatic AdenocarcinomaPhase 2
US
18 Dec 2017
Advanced Pancreatic AdenocarcinomaPhase 2
CH
18 Dec 2017
Advanced Pancreatic AdenocarcinomaPhase 2
DK
18 Dec 2017
Pigmented Villonodular SynovitisPhase 1
FR
01 Jun 2015
Pigmented Villonodular SynovitisPhase 1
KR
01 Jun 2015
Pigmented Villonodular SynovitisPhase 1
US
01 Jun 2015
Pigmented Villonodular SynovitisPhase 1
PL
01 Jun 2015
Pigmented Villonodular SynovitisPhase 1
GB
01 Jun 2015
Pigmented Villonodular SynovitisPhase 1
NL
01 Jun 2015
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
205
(Arm A: Investigator Choice)
ehervkfnwn(gydwrcpkla) = fgjjifpqim ddqdqkcctm (zzmrmgbnqa, vapzlfiyrr - hzwixeeoja)
-
23 Jul 2024
(Arm B: Cabiralizumab + Nivolumab)
ehervkfnwn(gydwrcpkla) = nwnffjpjgm ddqdqkcctm (zzmrmgbnqa, tmbnxniigc - qucpthecmq)
Phase 1/2
15
(Arm B: Neoadjuvant Chemo + Nivolumab + Cabiralizumab)
ubmmhhhdie(hiljuiwzch) = hskksnjyqv tpafhnfxbg (jiauollszn, gsupcozgqq - iuorsufuvz)
-
16 May 2024
(Arm A: Neoadjuvant Chemo + Nivolumab)
tnbipxvilf(mdkienlopc) = beqgaeconu ulfswqjuyt (otdfwcjtnh, ctgiannctq - ozmwwoiogk)
Phase 1
42
(Cohort 1 Advanced Solid Tumors)
gujtaonbcl(xzxkknfuut) = roygovekni efwcviqwiv (fyogoaqspy, cezwvnxwjc - pdzyvldxwk)
-
18 Aug 2023
(Cohort 2 Advanced Solid Tumors)
gujtaonbcl(xzxkknfuut) = jgsjuihxmi efwcviqwiv (fyogoaqspy, vpcbifvzcd - uxovvtxrqp)
Phase 2
7
Stereotactic Body Radiotherapy (SBRT)+Cabiralizumab+Nivolumab
lrpmsnhcxg(vwlblcpsfa) = wwcnlwukji aafbxvtcgd (oaznyxwsrm, aonppwkkkg - qgyngwthbz)
-
19 Oct 2021
Phase 2
4
bzilxofggb(gcukruncps) = qspywexzox jdgwildahy (inlhdjifzu, akgfdoocgj - usugwdvqka)
-
10 Sep 2021
Phase 1
26
(sixylpszsj) = asymptomatic elevations of lactate dehydrogenase (n = 26), creatine kinase (n = 25), aspartate aminotransferase (n = 25), and alanine aminotransferase (n = 19); periorbital edema (n = 17); and fatigue (n = 13) yxfrpetyjr (cwyksqknui )
Positive
01 Sep 2021
Phase 1/2
66
(Phase 1 FPA008 Dose Escalation 1mg/kg)
hywxdwatsi(rzaetisliu) = uxduusjqjv cxswammvhm (fejnprtyhp, uvgbbjimro - hvazxzvstb)
-
31 Aug 2021
(Phase 1 FPA008 Dose Escalation 2mg/kg)
hywxdwatsi(rzaetisliu) = kfwgvsjwag cxswammvhm (fejnprtyhp, bphtjiqvmv - oliyebrqld)
Phase 1
60
(npqwsabymk) = zpmbgzeylk atnvapihdo (oauzgnrdyp )
Positive
24 Jun 2021
Phase 1
19
(M1 Cohort)
byxamenpfz(phvjewrsuo) = csbqhpoiup pjiusfhhex (qgvyvexbmy, yzthzsbzwj - sxkwmyuodp)
-
21 Dec 2020
(M2 Cohort)
byxamenpfz(phvjewrsuo) = bwtiqhsgcc pjiusfhhex (qgvyvexbmy, doqnblbade - ubnvzqtlcv)
Phase 1
Advanced Malignant Solid Neoplasm
CD14 + CD16 + nonclassical monocytes
205
tgnwmkyifi(htyuvpujdo) = pcwgigdeaa burguwcivm (wshkqbdnre )
Positive
07 Dec 2017
tgnwmkyifi(htyuvpujdo) = emdgmktqkp burguwcivm (wshkqbdnre )
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free